Andrew Yan
Overview
Explore the profile of Andrew Yan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vecchiarelli E, Bentley R, Connelly K, Dorian P, Yan A, Mak S, et al.
PLoS One
. 2024 Mar;
19(3):e0294367.
PMID: 38478534
High volume endurance training may increase the risk of paroxysmal atrial fibrillation (AF) in middle-aged athletes. Limited data are available describing the cardiovascular phenotype of middle-aged endurance athletes, or the...
2.
Bainey K, Marquis-Gravel G, MacDonald B, Bewick D, Yan A, Turgeon R
PLoS One
. 2023 Sep;
18(9):e0291061.
PMID: 37656721
Introduction: Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However, DAPT duration is a concern in high bleeding risk (HBR)...
3.
Schroth D, Garg R, Bocova X, Hansmann J, Haass M, Yan A, et al.
Front Cardiovasc Med
. 2023 Jul;
10:1204232.
PMID: 37416926
Aims: Epidemiological surveillance has raised safety concerns for mRNA SARS-CoV-2-vaccination-related myocarditis. We aimed to analyze epidemiological, clinical and imaging findings associated with clinical outcomes in these patients in an international...
4.
Tran-Nguyen N, Condemi F, Yan A, Fremes S, Triverio P, Jimenez-Juan L
Ann Biomed Eng
. 2022 Jul;
50(12):1882-1894.
PMID: 35881267
Although coronary artery bypass graft (CABG) surgery is a well-established intervention, graft failure can occur, and the underlying mechanisms remain incompletely understood. The purpose of this prospective study is to...
5.
Reid C, AlTurki A, Yan A, So D, Ko D, Tanguay J, et al.
CJC Open
. 2020 May;
2(3):118-128.
PMID: 32462125
Background: There are important knowledge gaps in type 2 myocardial infarction (T2MI). Our primary objective was to compare the outcomes of patients with T2MI with those of patients with type...
6.
Block G, Rosenbaum D, Yan A, Chertow G
J Am Soc Nephrol
. 2019 Mar;
30(4):641-652.
PMID: 30846557
Background: Guidelines recommend reducing elevated serum phosphate in patients with CKD. Tenapanor, a minimally absorbed inhibitor of gastrointestinal sodium/hydrogen exchanger 3 (NHE3), reduces paracellular phosphate transport. Methods: In this phase...
7.
Block G, Rosenbaum D, Yan A, Greasley P, Chertow G, Wolf M
Nephrol Dial Transplant
. 2018 Apr;
34(2):339-346.
PMID: 29617976
Background: Elevated serum fibroblast growth factor 23 (FGF23) is strongly associated with cardiovascular risk and mortality. Tenapanor, an inhibitor of gastrointestinal sodium/hydrogen exchanger isoform 3, decreased serum phosphate in a...
8.
Rosenbaum D, Yan A, Jacobs J
Clin Drug Investig
. 2018 Jan;
38(4):341-351.
PMID: 29363027
Background: Tenapanor, a small molecule with minimal systemic availability, is a first-in-class sodium/hydrogen exchanger 3 (NHE3) inhibitor that acts in the gut. Here, we evaluate the pharmacodynamics and safety of...
9.
Brieger D, Hyun K, Chew D, Amerena J, Farouque O, MacIsaac A, et al.
Int J Cardiol
. 2016 Jul;
222:86-92.
PMID: 27467317
Aims: Variations in the delivery of evidence based care to high risk patients with Acute Coronary Syndromes (ACS) exist between hospitals. We hypothesised that the relative proportion of admitted high...
10.
Huynh T, Kouz S, Yan A, Yan A, Danchin N, OLoughlin J, et al.
Am Heart J
. 2013 Jul;
166(1):58-63.
PMID: 23816022
Background: Despite the availability of several acute coronary syndrome (ACS) prognostic risk scores, there is no appropriate score for early-risk stratification at the time of the first medical contact with...